International Journal of Pharmaceutics: X

AUG 19, 2026 · JOURNAL ARTICLE

Targeted Nanoparticle Delivery CRISPR/Cas9: overcoming biological barriers, enhancing stability, and improving therapeutic precision.

International Journal of Pharmaceutics: X

This is a narrative review proposing conceptual frameworks for nanoparticle-mediated CRISPR delivery; it does not report primary experimental data, efficacy outcomes, or comparative evidence.

JUL 13, 2026 · JOURNAL ARTICLE

Exosome-like nanoparticles derived from Astragali Radix-Curcumae Rhizoma co-decoction enhance oral bioavailability and provide synergistic efficacy and reduced toxicity in combination with 5-fluorouracil for lung cancer therapy.

International Journal of Pharmaceutics: X

Preclinical mouse model data showing enhanced bioavailability and synergistic efficacy; no human safety or efficacy data yet available.

JUL 11, 2026 · JOURNAL ARTICLE

Artesunate-loaded bovine serum albumin nanoplatform with metal-polyphenol network coating for ferroptosis-driven breast cancer therapy.

International Journal of Pharmaceutics: X

Preclinical proof-of-concept in cell and animal models showing a novel nanoparticle formulation induces ferroptosis and tumor inhibition, but lacks human efficacy data, safety characterization, and direct comparator controls.

JUL 11, 2026 · JOURNAL ARTICLE

Emerging copper-based hollow nanoplatforms for cancer treatment.

International Journal of Pharmaceutics: X

This is a narrative review synthesizing preclinical and emerging evidence on copper-based nanoplatforms; no original experimental data, clinical trials, or comparative efficacy data are presented.

JUL 8, 2026 · JOURNAL ARTICLE

ZIF-8 nanoplatform coordinating Zn2+ overload and STING activation for enhanced prostate cancer immunotherapy.

International Journal of Pharmaceutics: X

Preclinical in vitro and in vivo study of a novel nanoplatform in experimental models; no clinical trials or human data reported; mechanism-focused work showing promise but not yet tested in patients.

JUL 2, 2026 · JOURNAL ARTICLE

Biomimetic co-delivery nanoplatform overcomes CAF- and TAM-induced immunosuppression to augment therapeutic efficacy against triple-negative breast cancer.

International Journal of Pharmaceutics: X

Preclinical murine model study demonstrates nanoplatform remodels tumor microenvironment and enhances immune checkpoint blockade efficacy in triple-negative breast cancer.

JUL 2, 2026 · METHODS/FORMULATION DEVELOPMENT STUDY

Peptide-functionalized nanoemulsions with exendin-4 as a model ligand.

International Journal of Pharmaceutics: X

In vitro cell culture study demonstrating enhanced GLP-1R activation by peptide-functionalized nanoemulsions with no clinical or in vivo efficacy data.

JUN 29, 2026 · JOURNAL ARTICLE

ROS-Activatable "off-on" Fluorescent Prodrug Loaded Micelles for Targeted Therapy and in Situ Imaging of Breast Cancer Cells.

International Journal of Pharmaceutics: X

Preclinical cellular assay data demonstrating targeted drug delivery and imaging in breast cancer cells with promising uptake and cytotoxicity results.